GSK (GSK) announced that the European Medicines Agency, EMA, has accepted the company’s regulatory application to expand the use of its adjuvanted recombinant respiratory syncytial virus, RSV, vaccine to include adults from 18 years of age. Arexvy was the first RSV vaccine approved in the European Economic Area for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older, and for those aged 50-59 years who are at increased risk for RSV disease. A European regulatory decision on this submission is anticipated in H1 2026. GSK is continuing to seek expanded indications for its RSV vaccine in other geographies including the US and Japan.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- Senators to propose ban on drug ads to consumers, WSJ reports
- GSK licenses Shigella vaccine candidate to Bharat Biotech
- RFK Jr. names eight members to vaccine panel, WSJ reports
- RFK Jr. names new CDC vaccine advisory panel picks, STAT reports
- Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue